<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190514043582N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-06-18</date_registration>
      <primary_sponsor>Shahid  Rajaee Cardiovascular Center Tehran</primary_sponsor>
      <public_title>Comparison of the use of Epinephrine, Norepinephrine and Phenylephrine drugs during cardiopulmonary bypass on brain oxygenation</public_title>
      <acronym></acronym>
      <scientific_title>The study of the effect of the use of Epinephrine, Norepinephrine and Phenylephrine drugs during cardiopulmonary bypass on brain oxygenation in patients undergoing open heart surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-08-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39623</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The randomization method Will be performed as a six-point random block, and patients will be assigned to three groups according to the randomization list, Blinding description: in this study,direction blind of the method six blocks are used.
And practical none of the patients are aware of the grouping of drugs. In the beginning of the surgery, one of the three inotropic drugs was studied, without label and only on the basis of the randomization method at the disposal of the perfusionist who is responsible for the bypass.and he did not know the type of drug during the bypass pump. If the median arterial pressure drops to less than 50 mmHg, it will use a medication of one milliliter. As well as a person who records patient information does not have any sort of information grouping.</study_design>
      <phase>1-2</phase>
      <hc_freetext>hypotension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a norepinephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA). Intervention 2: Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a Epinephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA). Intervention 3: Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a Phenylephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Privacy Patients</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Rostami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajaee Cardiovascular Center,Valiasr street,Ayatollah Hashemi Highway,Tehran,iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1444635458</zip>
        <telephone>+98 21 6653 9401</telephone>
        <email>rostami_reza755@yahoo.com</email>
        <affiliation>Shahid Rajaee Cardiovascular heart center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Rostami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajaee Cardiovascular Center,valiasr street,Ayatollah Hashemi Highway,Tehran,iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19956114331</zip>
        <telephone>+98 21 2392 2454</telephone>
        <email>rostami_reza755@yahoo.com</email>
        <affiliation>shahid rajai cardiovascular center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient satisfaction to participate in the study
Patients undergoing elective open-heart surgery (Coronary artery bypass graft surgery and heart valve surgery)
Patients older than 18 years
No history of transient cerebral ischemic disease or stroke
No history of narrowing of the carotid arteries by more than 70% or no clear stenosis
No history of previous cardiac surgery
Not having of uncontrolled diabetes (with the opinion of an internal specialist) or the absence of uncontrolled blood pressure (with the opinion of the cardiologist)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Heart arrest before starting cardiac bypass
No need to prescribe inotropic drugs during surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I95.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other hypotension</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a norepinephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA).</i_keyword>
      <i_keyword>Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a Epinephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA).</i_keyword>
      <i_keyword>Intervention group:  At the entrance to the operating room, patients will receive oxygen from the nasal cannula at 2 liters per minute. The ECG and average arterial blood pressure monitors and the cerebral-oxymeter system sensors will be connected to the patients before the start of anesthesia to determine the saturation of the brain oxygenation. Based on the random categorization of patients in the three groups during CPB to maintain and maintain the blood pressure of the patients Above 60 mmHg after increasing flow, if needed, a Phenylephrine dose of 5 to 10 micrograms will be used. Arterial blood pressure, arterial oxygen saturation, and ScO2 will be recorded for each patient before the starting of anesthesia and  the bypass. During the CPB period, the oxygen saturation saturation of 120, 150 and 180 seconds after injection of Inotrope drugs will be measured. The mean of arterial blood pressure, PaO2, body temperature of the patient, ScO2, will be displayed and recorded during the CPB period through the monitor. The mean arterial blood pressure and the measurement of the mean arterial pressure It will be done. ScO2 is also measured and displayed by brain oximetric monitors (INVOS, INVOS Somanetics, Troy, MI, USA).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Brain Oxygenation. Timepoint: 120, 150 and 180 seconds after injections of inotropic drugs during cardiopulmonary bypass. Method of measurement: Monitoring of cerebral oxygen saturation.</prim_outcome>
      <prim_outcome>Blood lactate level. Timepoint: Before the starting of cardiopulmonary bypass and during anesthesia,during cardiopulmonary bypasses at certain intervals and after the end of the cardiopulmonary artery bypass. Method of measurement: Arterial blood sample and arterial gas analyzer.</prim_outcome>
      <prim_outcome>PH Level. Timepoint: Before starting of cardiopulmonary bypass and during anesthesia,During cardiopulmonary bypasses at certain intervals and after the end of the cardiopulmonary artery bypass. Method of measurement: Arterial blood sample and arterial gas analyzer.</prim_outcome>
      <prim_outcome>Duration of mechanical ventilation after surgery in patients. Timepoint: After surgery and in the intensive care unit. Method of measurement: The length of time the patient is in the intensive care unit is connected to the ventilator.</prim_outcome>
      <prim_outcome>The duration of return of normal heart rhythm and the need for defibrillator and the need to use pacemakers. Timepoint: After surgery and in the intensive care unit. Method of measurement: Within 48 hours after the end of the pulmonary bypass.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The rate of Use of Epinephrine, Norepinephrine and Phenylephrine for Maintaining Mean Arterial Pressure in the Range of 60 to 80 mmHg. Timepoint: At a time when the patient's blood pressure falls below 60 mm Hg during cardiopulmonary bypass. Method of measurement: Observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid  Rajaee Cardiovascular Center Tehran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-27</approval_date>
        <contact_name>Ethict commitee of Shahid Rajaei Cardiovascular Medical and Research heart center</contact_name>
        <contact_address>Shahid Rajaee Cardiovascular Center,valiasr street,Ayatollah Hashemi Highway,Tehran,iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
